Hubei Guangji Pharmaceutical Co.Ltd(000952) 3 on March 24, the annual report of 2021 was released. In 2021, the net profit attributable to the owner of the parent company was 110 million yuan, with a year-on-year increase of 47.5%; The operating revenue was 837 million yuan, a year-on-year increase of 21.64%; Deduct non net profit of 65.64 million yuan, with a year-on-year increase of 69.85%; The basic earnings per share was 0.3201 yuan, a year-on-year increase of 43.41%. The company plans to distribute a cash dividend of 0.6 yuan for every 10 shares to all shareholders.
Hubei Guangji Pharmaceutical Co.Ltd(000952) said that in 2021, facing the market changes and competitive pressure of the pharmaceutical industry, the management of the company actively overcame the phased impact brought by the price reduction of some products and the rise of procurement costs of some raw materials, maintained the stable development of the overall operation, continued to focus on scientific and technological innovation and strengthening internal management, paid attention to the market and management outside, and continued to make innovation and breakthroughs to ensure the sustainable development of the company.
Hubei Guangji Pharmaceutical Co.Ltd(000952) said that during the reporting period, the company actively expanded new products. First, build a product cluster characterized by B vitamins, strengthen the core competitiveness of VB2 products, accelerate the EU registration of “1831” and realize the sales of high-quality VB2 as soon as possible. Accelerate the extension and development of VB6 industrial chain and accelerate the industrial production of pyridoxal phosphate. Accelerate the construction of VB12 (1%) comprehensive utilization project with an annual output of 1000 tons, enrich the company’s vitamin product categories, and promote the development of VB12 food grade and pharmaceutical grade. The second is to evaluate the consistency of pharmaceutical products and speed up the R & D and project approval of moxifloxacin hydrochloride and other products. Third, independent research and development of health products and multi vitamin tablets, and cooperation in the development of high value-added dietary supplement products.
According to Hubei Guangji Pharmaceutical Co.Ltd(000952) annual report, in 2021, the company’s important events continued. On September 3, 2021, the company held the 8th meeting of the 10th board of directors, deliberated and approved the proposal on signing the product cooperation agreement between the company and Sinopharm holding Hubei Co., Ltd., signed this cooperation agreement, aiming at realizing the complementary advantages and resource sharing of both parties, and jointly committed to the API and pharmaceutical preparation industry by giving full play to their respective resources and advantages, It is conducive to further enhance the company’s market competitiveness and sustainable profitability, and will bring good social and economic benefits to the company.
In order to further establish and improve the company’s long-term incentive and restraint mechanism, attract and retain excellent talents, and fully mobilize the enthusiasm of the company’s directors, senior managers, middle-level cadres and core technical / business personnel, during the reporting period, the company implemented the 2021 restricted stock incentive plan, which combines the interests of shareholders, the company and the personal interests of the core team, so as to make all parties pay common attention and promote the long-term development of the company.
In order to realize the company’s “API + Preparation” two wheel driven development strategy, we will make efforts at both ends of sales and R & D, forming a virtuous circle of R & D, production and sales Hubei Guangji Pharmaceutical Co.Ltd(000952) plans to introduce the R & D team in the way of “mixed reform” and jointly invest with Wuhan Tongtai Qixin enterprise management consulting partnership to establish a holding subsidiary. This investment will be conducive to realizing the development strategy of Hubei Guangji Pharmaceutical Co.Ltd(000952) “API + Preparation”; It is conducive to make up for the company’s lack of preparation R & D capacity, establish a high-quality product development platform, accelerate product development, form a community of interests with the R & D team, stimulate R & D vitality and create value for the company.
